During the 65th American Society of Hematology Annual Meeting and Exposition, Dima presented results from a retrospective analysis to evaluate the real-world safety and efficacy of teclistamab, with a focus on patients who would have been ineligible for the MajesTEC-1 trial. We summarize the key findings in this podcast.
To read this article on the Multiple Myeloma Hub, click here: https://multiplemyelomahub.com/medical-information/teclistamab-real-world-safety-and-efficacy
This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
","author_name":"Scientific Education Support"}